A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Advanced or Metastatic Colorectal Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 225 (planned)
- Started
- Jul 29, 2022
- Main results expected
- Apr 27, 2027
- Fully finished
- May 11, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohorts A, B, and C: Objective Response Rate (ORR)
Measured over: Up to 4 years 3 months
Cohorts Ph1b-D and Ph1b-E: Number of Participants with Dose-limiting Toxicity (DLT)
Measured over: Up to 4 years 3 months
Cohorts Ph1b-D and Ph1b-E: Number of Participants with DLT by Severity
Measured over: Up to 4 years 3 months
Cohorts D and E: Number of Participants with Adverse Events (AE)
Measured over: Up to 4 years 3 months
Cohorts D and E: Number of Participants with Laboratory Values Abnormalities
Measured over: Up to 4 years 3 months
Cohorts D and E: Number of Participants with Vital Signs Abnormalities
Measured over: Up to 4 years 3 months
Cohorts F: Number of Participants with Adverse Events (AE)
Measured over: Up to 4 years 3 months
Cohorts F: Number of Participants with Laboratory Values Abnormalities
Measured over: Up to 4 years 3 months
Cohorts F: Number of Participants with Vital Signs Abnormalities
Measured over: Up to 4 years 3 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05379595 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC